Evaluation of all 74 enrolled and evaluable patients at 12 months post‐treatment showed a trend of improvement in BCVA in patients who received the higher cell dose compared to the sham control.
1
—
—
Evaluation of all 74 enrolled and evaluable patients at 12 months post‐treatment showed a trend of improvement in BCVA in patients who received the higher cell dose compared to the sham control.